Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia

Journal of Psychopharmacology

Volumn 19, Issue 5, 2005, Pages 473-482

  Layton, Deborah ^a,b   Harris, Scott ^c   Wilton, Lynda V ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Atypical antipsychotics; Cerebrovascular accidents; Dementia; Observational cohort studies; Olanzapine; Prescription event monitoring; Quetiapine; Risperidone; Transient ischaemic attacks

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; DRUG INDICATION; FEMALE; GENERAL PRACTICE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; DEMENTIA; DIBENZOTHIAZEPINES; ENGLAND; FAMILY PRACTICE; FEMALE; HUMANS; INCIDENCE; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; RISK FACTORS; RISPERIDONE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 25844449630     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105056524     Document Type: Article

References (34)

1. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106
2. Bhana N, Spencer C M (2000) Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs Aging 16: 451-471
3. Committee on Safety of Medicine, London, DoH (2004) Atypical antipsychotic drugs and stroke. Web address: http://www.mhra.gov.uk/news/ antipsystroke_9304.htm. Date accessed 9/3/2004
4. Dear Healthcare Professional (2002) Risperdal* (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials. Janssen-Ortho, Canada
5. Dear Healthcare Professional (2004a) The risk of cerebrovascular adverse events (CVAE) in elderly patients with dementia: important changes to the summary of product characteristics relating to use of risperidone. Janssen-Cilag Ltd, High Wycombe
6. Dear Healthcare Professional (2004b) Zyprexa*(olanzapine) and cerebrovascular adverse events in placebo-controlled elderly dementia trials. Eli Lilly Canada Inc, Canada
7. Dear Healthcare Professional (2004c) Important safety information on olanzepine and risk of mortality and stroke in elderly patients with dementia-related psychosis and/or behavioural disturbances. Eli Lilly and Company Ltd, Basingstoke
8. Douglas-Hall P, Fuller A, Gill-Banham S. (2001) An analysis of off-licence prescribing in psychiatric medicine. Pharmaceutical Journal 267: 890-891
9. Eli Lilly and Company Limited (2004) Summary of product characteristics Zyprexa (olanzapine). Eli Lilly and Company Ltd
10. Faculty of the Psychiatry of Old Age (2005) Prescribing update for old age psychiatrists. Website address: www.rcpsych.ac.uk/college/faculty/oap/BPSD. pdf. Date accessed 05/04/2005
11. Haddad P M, Anderson I M (2002) Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62: 1649-1671
12. Herrmann N, Mamdani M, Lanctot K L. (2004) Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 161: 1113-1115
13. Irish Medicines Board (2004) IMB stresses Important New Safety Information on Olanzapine
14. Janssen-Cilag Ltd (2004) Summary of product characteristics Risperdal (risperidone). Janssen-Cilag Ltd
15. Kirchner V, Kelly CA, Harvey R J. (2004) Thioridazine for dementia (Cochrane Review). John Wiley & Sons Ltd, Chichester
16. Layton D, Heeley E, Hughes K, Shakir SA (2003) Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology (Oxford) 42: 622-631
17. Lee P E, Gill S S, Freedman M, Bronskill S E, Hillmer M P, Rochan P A. (2004) Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 329: 75
18. Lowe-Ponsford F, Baldwin D (2000) Off-label prescribing by psychiatrists. Psychiatric Bulletin 24: 415-417
19. Machin D, Campbell M, Payers P, Pinol A P Y. (1997a) Sample Size Tables for Clinical Studies. Table 7.1. Blackwell Science Ltd, Oxford
20. Machin D, Campbell M, Payers P, Pinol A P Y (1997b) Sample Size Tables for Clinical Studies. Table 7.2. Blackwell Science Ltd, Oxford
21. Mann R D, Rawlins M D, Fletcher P (1992) Age and the spontaneous reporting of adverse reactions in the United Kingdom. Pharmacoepidemiol Drug Saf 1: 19-23
22. Medsafe (2003) Risperidone and cerebrovascular accidents in elderly patients with dementia. Web address: http://www.medsafe.govt.nz. Date accessed 9/3/2004
23. Medwatch (2003) The FDA Safety Information and Adverse Event Reporting Program 2003 Safety Alert Risperdal (risperidone). Dear healthcare professional letter. Web address: http://www.fda.gov/medwatch/SAFETY2005/risperdal.htm. Date accessed 02/12/2003.
24. National Institute of Clinical Excellence (2002) Guidance on the use of newer (atypical) antipsychotic agents for the treatment of schizophrenia. NICE, London
25. Oborne C A, Hooper R, Swift C G, Jackson S H. (2002) An indicator of appropriate neuroleptic prescribing in nursing homes. Age Ageing 31: 435-439
26. Rasanen S, Hakko H, Villo K, Meyer-Rochow V B, Moring J. (2003) Excess mortality among long-stay psychiatric patients in northern Finland. Soc Psychiatry Psychiatr Epidemiol 38: 297-304
27. Schmidt R, Schmidt H, Fazekas F. (2000) Vascular risk factors in dementia. J Neurol 247: 81-87
28. Schneider L S, Tariot P N, Lyketsos C G, Dugerman K S, Davis K L, Davis S, Hsiao J K, Veste D V, Katz I R, Olin J T, Pollock B G, Rabins P V, Rosenheck R A, Small G W, Lebowitz B, Lieberman J A. (2001) National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. American Journal of Geriatric Psychiatry 9: 346-360
29. Shakir S A (2002) PEM in the UK. In Mann R D, Andrews E (eds), Pharmacovigilance. John Wiley & Sons Ltd, Chichester, pp. 333-344
30. Sink K M, Holden K F, Yaffe K. (2005) Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293: 596-608
31. Strom B (1994) Sample size considerations for pharmacoepidemiology studies. In Strom B (ed.), Pharmacoepidemiology. John Wiley & Sons, Chichester
32. The European Agency for the Evaluation of Medicinal Products (2004) Public statement on the safety of olanzapine (Zyprexa zyprexa vclotab). Ref EMEA/CPMP/856/04/Final. London.
33. West S, Strom B L et al. (2002) Validity of pharmacoepidemiology drug and diagnosis data. In Strom B L (ed.), Pharmacoepidemiology. John Wiley & Sons Ltd, Chichester, pp. 661-705
34. Wooltorton E (2002) Practice Health Drug Alerts. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 167: 1269-1270